Contract manufacturers of APIs and intermediates are cautiously optimistic.
The tide may be turning for contract manufacturing organizations (CMOs) of active pharmaceutical ingredients (APIs) and intermediates. In gauging opinion at Informex, the trade show of custom and batch manufactures, held in New Orleans Jan. 29–Feb. 1, 2008, many CMOs, armed with improved profitability and investment plans, were fairly upbeat following more subdued views from recent years.
Patricia Van Arnum
Signs of optimism were apparent in the results of a business survey released at Informex by the Synthetic Organic Chemical Manufacturers Association (SOCMA). SOMCAis the US-based trade association of custom and batch manufacturers, and 92% of survey respondents characterized current business conditions as "excellent/very good" (54%) or "good" (38%). This outlook is better than in 2006, when only 82% rated business conditions as "excellent/very good" (53%) or "good" (29%).
In speaking with several CMOs, most concur with this sanguine view and see their growth largely being driven by emerging pharmaceutical companies. Their optimism, however, is tempered by the "R" word—recession—and the attendant macroeconomic factors that could affect the financing flow into these smaller companies. "Tighter lending practices and reduced private and equity investment could potentially hamper the liquidity of small bio and pharma companies, and this would be a concern for us," said one CMO.
As to Big Pharma, many CMOs say they have yet to see any uptick from recent manufacturing rationalization and intentions to increase outsourcing."Big Pharma has enough internal capacity. Whether companies will increase outsourcing remains to be seen," said one CMO.
Offer your opinions on this and other topics at blog.pharmtech.com, our blog, which goes live later this month at Interphex.
Patricia Van Arnum is a senior editor with Pharmaceutical Technology, pvanarnum@advanstar.com
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.